2019-20 coronavirus outbreak

Immunosuppression

Booster (rocketry)

Biology

Virology

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Outbreak

Rheumatoid arthritis

Coronavirus disease 2019 (COVID-19)

Booster dose

Paleontology

Immunology

Physics

Vaccination schedule

Astronomy

Vaccination

Immunization

Infectious disease (medical specialty)

Internal medicine

Immunogenicity

Series (stratigraphy)

Medicine

Disease

Rituximab

Antibody

Annals of the Rheumatic Diseases

An attenuated humoral response to SARS-CoV-2 vaccination has been observed in some patients with autoimmune disease,1 2 and immunosuppressed status has been associated with an increased risk of COVID-19 infection despite vaccination.3 Recent studies have demonstrated enhanced humoral response to third-dose SARS-CoV-2 vaccination in immunosuppressed transplant patients,4 5 but the immunogenicity of booster vaccination in other immunosuppressed populations is unknown. Thus, we sought to describe the humoral response in patients with autoimmune disease who received a booster SARS-CoV-2 vaccine.Using our prospective cohort of patients with autoimmune disease,5 we included patients who reported receipt of a single booster dose of SARS-CoV-2 mRNA or adenovirus vector vaccine between 10 April and 11 June 2021. We observed serial anti-spike antibody responses among these participants.A total of 18 participants received a booster SARS-CoV-2 vaccine dose (table 1). Most (13/18) were women with median (IQR) age of 55 (44–63) years. The most common autoimmune diagnoses included myositis (n=6) and inflammatory arthritis (n=3). Most (14/18) were on antimetabolite therapy; mycophenolate was the most commonly reported immunosuppressive therapy (n=8), with a median (IQR) daily dose of 3000 mg (2500–3000 mg). Participants completed initial vaccination with either Pfizer (n=8), Moderna (n=6) or Johnson & Johnson/Janssen (J&J) Ad26.COV2.S (n=4).View this table:Table 1 Vaccines administered, autoimmune diagnoses, immunosuppression and peri-vaccination management with longitudinal anti-spike antibody responsesAnti-spike antibodies, evaluated via Roche Elecsys anti-RBD pan-Ig were negative in 10 participants (anti-RBD <0.8 U/mL) and low-positive …

Booster-dose SARS-CoV-2 vaccination in patients with autoimmune disease: a case series